Literature DB >> 11168786

Biliary dysplasia, cell proliferation and nuclear DNA-fragmentation in primary sclerosing cholangitis with and without cholangiocarcinoma.

A Bergquist1, H Glaumann, P Stål, G S Wang, U Broomé.   

Abstract

OBJECTIVES: To study the extent of biliary dysplasia, and the degree of cell proliferation and apoptosis in bile duct cells (BDC) from patients with primary sclerosing cholangitis (PSC), with and without cholangiocarcinoma (CC).
METHODS: Specimens of liver tissue from 16 patients suffering from PSC and CC, and 16 patients with end-stage PSC without cancer, were investigated. Histological evaluation of presence of biliary dysplasia and bile duct proliferation was made. Immunohistochemistry, applying antibodies against Ki-67, p53 and bcl-2, was used. Nuclear DNA fragmentation was assessed by in situ DNA labelling (ApopTag). The numbers of positive cells expressed as a percentage of the total number of BDCs constituted the labelling index (LI).
RESULTS: Bile duct dysplasia was significantly more frequent in nontumorous liver tissue from patients with PSC and CC than from patients having end-stage PSC without cancer (P < 0.05). Patients with biliary dysplasia had a higher frequency of marked bile duct proliferation (P < 0.01) than patients without dysplasia. In tumour tissue, the LI for Ki-67 positive nuclei was more than four times the LI of nuclear DNA fragmentation (P < 0.01). Ki-67, bcl-2, p53 or DNA fragmentation were not significantly different in nontumorous liver tissue from patients with and without CC. Immunohistochemical staining for p53 was positive in 75% of the tumours, whilst in nontumorous tissue no such overexpression was found.
CONCLUSION: PSC patients with CC more often display biliary dysplasia than those with end-stage PSC, indicating that biliary dysplasia may be a precancerous stage in PSC. Additionally, p53 mutation seems to be a late event in tumour development, since no p53 expression was found in the premalignant areas with nontumorous BDC.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11168786     DOI: 10.1046/j.1365-2796.2001.00775.x

Source DB:  PubMed          Journal:  J Intern Med        ISSN: 0954-6820            Impact factor:   8.989


  15 in total

1.  Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document.

Authors:  S A Khan; B R Davidson; R Goldin; S P Pereira; W M C Rosenberg; S D Taylor-Robinson; A V Thillainayagam; H C Thomas; M R Thursz; H Wasan
Journal:  Gut       Date:  2002-11       Impact factor: 23.059

2.  The value of thioredoxin family proteins and proliferation markers in dysplastic and malignant gallbladders in patients with primary sclerosing cholangitis.

Authors:  Karouk Said; Hans Glaumann; Mikael Björnstedt; Annika Bergquist
Journal:  Dig Dis Sci       Date:  2012-02-28       Impact factor: 3.199

3.  Biliary multifocal chromosomal polysomy and cholangiocarcinoma in primary sclerosing cholangitis.

Authors:  John E Eaton; Emily G Barr Fritcher; Gregory J Gores; Elizabeth J Atkinson; James H Tabibian; Mark D Topazian; Andrea A Gossard; Kevin C Halling; Benjamin R Kipp; Konstantinos N Lazaridis
Journal:  Am J Gastroenterol       Date:  2015-01-27       Impact factor: 10.864

4.  DNA flow cytometric analysis of paraffin-embedded tissue for the diagnosis of malignancy in bile duct biopsies.

Authors:  Hannah Lee; Peter S Rabinovitch; Aras N Mattis; Sanjay Kakar; Won-Tak Choi
Journal:  Hum Pathol       Date:  2020-04-06       Impact factor: 3.466

5.  Extensive biliary intraepithelial neoplasia (BilIN) and multifocal early intrahepatic cholangiocarcinoma in non-biliary cirrhosis.

Authors:  Anne-Laure Rougemont; Muriel Genevay; Thomas A McKee; Magali Gremaud; Gilles Mentha; Laura Rubbia-Brandt
Journal:  Virchows Arch       Date:  2010-04-29       Impact factor: 4.064

6.  Multistep carcinogenesis of perihilar cholangiocarcinoma arising in the intrahepatic large bile ducts.

Authors:  Yasuni Nakanuma; Motoko Sasaki; Yasunori Sato; Xiangshan Ren; Hiroko Ikeda; Kenichi Harada
Journal:  World J Hepatol       Date:  2009-10-31

Review 7.  Cancer surveillance in patients with primary sclerosing cholangitis.

Authors:  Nataliya Razumilava; Gregory J Gores; Keith D Lindor
Journal:  Hepatology       Date:  2011-11       Impact factor: 17.425

Review 8.  Preemptive surgery for premalignant foregut lesions.

Authors:  Rohit R Sharma; Mark J London; Laura L Magenta; Mitchell C Posner; Kevin K Roggin
Journal:  J Gastrointest Surg       Date:  2009-06-10       Impact factor: 3.452

Review 9.  Clinical features and management of primary sclerosing cholangitis.

Authors:  Marina-G Silveira; Keith-D Lindor
Journal:  World J Gastroenterol       Date:  2008-06-07       Impact factor: 5.742

10.  Expression of Bcl-2 and Bax in extrahepatic biliary tract carcinoma and dysplasia.

Authors:  Sheng-Mian Li; Shu-Kun Yao; Nobuyoshi Yamamura; Toshitsugu Nakamura
Journal:  World J Gastroenterol       Date:  2003-11       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.